




Claims

1. A compound represented by the formula (I) or the formula (II):



5

wherein X is




;

ring A is an optionally substituted saturated or
10 unsaturated cyclic hydrocarbon group or saturated or
unsaturated heterocyclic group;

ring B is a benzene ring optionally further having one
to four substituents;


R₁ is an optionally substituted lower alkyl group, an
15 optionally substituted aryl group, a substituted amido
group or an optionally substituted amino group;

each of R₂ to R₄, whether identical or not, is a hydrogen
atom, a saturated or unsaturated hydrocarbon group or a
saturated or unsaturated heterocyclic group (R₃ and R₄
20 may bind together to form a ring), except that the
compounds shown below are excluded,



or a pharmaceutically acceptable salt thereof.

- 5 2. The compound of claim 1, wherein the compound represented by the formula (I) is a compound represented by the formula (I'):



wherein ring A' is an optionally substituted saturated
 10 or unsaturated heterocyclic group; the other symbols are as defined in claim 1,
 or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2, wherein in the formula (I'),
 15 the ring A' is a saturated or unsaturated cyclic hydrocarbon group or saturated or unsaturated heterocyclic group optionally substituted by at least one substituent selected from the group consisting of saturated or unsaturated cyclic hydrocarbon groups,
 20 saturated or unsaturated heterocyclic groups, carboxyl

groups, substituted amido groups and optionally substituted lower alkyl groups,
or a pharmaceutically acceptable salt thereof.

5 4. The compound of claim 2, wherein in the formula (I'), the ring A' is a saturated or unsaturated heterocyclic group having both any one substituent selected from the group consisting of saturated or unsaturated cyclic hydrocarbon groups and saturated or unsaturated
10 heterocyclic groups, and any one substituent selected from the group consisting of carboxyl groups, substituted amido groups and optionally substituted lower alkyl groups,
or a pharmaceutically acceptable salt thereof.

15

5. The compound of claim 1, wherein in the formula (II), the ring formed by mutually binding R₃ and R₄ is a saturated or unsaturated cyclic hydrocarbon group or a saturated or unsaturated heterocyclic group optionally
20 having at least one substituent selected from the group consisting of carboxyl groups, substituted amido groups and optionally substituted lower alkyl groups,
or a pharmaceutically acceptable salt thereof.

25 6. The compound of claim 5, wherein in the formula (II), the ring formed by binding of R₃ and R₄ is a saturated or unsaturated cyclic hydrocarbon group optionally having at least one substituent selected from the group consisting of carboxyl groups, substituted amido groups
30 and optionally substituted lower alkyl groups,
or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6, wherein the saturated or unsaturated cyclic hydrocarbon group is indene,
35 or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising, as an active ingredient, the compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof.

5

9. The pharmaceutical composition of claim 8, which is for the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy.


10

10. A pharmaceutical composition comprising, as an active ingredient, a compound that specifically binds to a protein having the amino acid sequence of SEQ ID NO:2.

15 11. A pharmaceutical composition comprising, as an active ingredient, a compound that specifically binds to a protein having the amino acid sequence of SEQ ID NO:2, wherein one or more amino acids are deleted, substituted or added, and which;

20 (i) binds to a compound of formula 1, and

(ii) does not bind to a compound of formula 2




12. A pharmaceutical composition comprising, as an active ingredient, a compound that specifically binds to a protein having the amino acid sequence of SEQ ID NO:3.

13. A pharmaceutical composition comprising, as an

active ingredient, a compound that specifically binds to a protein having the amino acid sequence of SEQ ID NO:3, wherein one or more amino acids are deleted, substituted or added, and which;

- 5 (i) binds to a compound of formula 1, and
(ii) does not bind to a compound of formula 2



14. The pharmaceutical composition of any one of claims
10 10 to 13, which is for the treatment of a disease
selected from the group consisting of a proliferative
disease, an inflammatory disease and an encephalopathy.

15. The pharmaceutical composition of claim 14, wherein
15 the proliferative disease is at least one kind selected
from the group consisting of familial adenomatous
polyposis, esophageal cancer, small-cell lung cancer,
prostatic cancer, breast cancer, non-small-cell cancer
and ovarian cancer.

20

16. A pharmaceutical composition comprising, as an
active ingredient, a compound that specifically binds to
KSRP.

25 17. A pharmaceutical composition comprising, as an
active ingredient, a compound that regulates the
expression of KSRP.

18. A pharmaceutical composition comprising, as an active ingredient, a compound that regulates the activity of KSRP.

5 19. The pharmaceutical composition of any one of claims 16 to 18, which is for the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy.

10 20. The pharmaceutical composition of claim 19, wherein the proliferative disease is at least one kind selected from the group consisting of familial adenomatous polyposis, esophageal cancer, small-cell lung cancer, prostatic cancer, breast cancer, non-small-cell cancer
15 and ovarian cancer.

21. A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory
20 disease and an encephalopathy, which comprises the steps shown below;

(1) a step of bringing KSRP or a functional fragment thereof into contact with a test compound,
(2) a step of determining whether or not the test
25 compound specifically binds to KSRP or a functional fragment thereof, and
(3) a step of selecting a test compound that specifically binds to KSRP or a functional fragment thereof in the step (2) above.

30

22. A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which comprises the steps
35 shown below;

(1) a step of bringing a protein having the amino acid sequence of SEQ ID NO:2 or a functional fragment thereof into contact with a test compound,

(2) a step of determining whether or not the test compound specifically binds to the protein or a functional fragment thereof, and


(3) a step of selecting a test compound that specifically binds to the protein or a functional fragment thereof in the step (2) above.

10

23. A method for screening for a compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which comprises the steps shown below;

(1) a step of bringing a protein having the amino acid sequence of SEQ ID NO:2, wherein one or more amino acids are deleted, substituted or added, and which:

(i) binds to a compound of formula 1, and
(ii) does not bind to a compound of formula 2



or a functional fragment thereof into contact with a test compound,

(2) a step of determining whether or not the test compound specifically binds to the protein or a functional fragment thereof, and

(3) a step of selecting a test compound that specifically binds to the protein or a functional

fragment thereof in the step (2) above.

24. A method for screening for a compound useful in the treatment of a disease selected from the group
5 consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which comprises the steps shown below;

(1) a step of bringing a protein having the amino acid sequence of SEQ ID NO:3 or a functional fragment thereof
10 into contact with a test compound,

(2) a step of determining whether or not the test compound specifically binds to the protein or a functional fragment thereof, and


(3) a step of selecting a test compound that
15 specifically binds to the protein or a functional fragment thereof in the step (2) above.

25. A method for screening for a compound useful in the treatment of a disease selected from the group
20 consisting of a proliferative disease, an inflammatory disease and an encephalopathy, which comprises the steps shown below;

(1) a step of bringing a protein having the amino acid sequence of SEQ ID NO:3, wherein one or more amino acids
25 are deleted, substituted or added, and which:

(i) binds to a compound of formula 1, and

(ii) does not bind to a compound of formula 2



or a functional fragment thereof into contact with a test compound,

(2) a step of determining whether or not the test compound specifically binds to the protein or a functional fragment thereof, and

(3) a step of selecting a test compound that specifically binds to the protein or a functional fragment thereof in the step (2) above.

26. A compound useful in the treatment of a disease selected from the group consisting of a proliferative disease, an inflammatory disease and an encephalopathy, obtained by the screening method of any one of claims 21 to 25.

15